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Abstract
Background: Human head and neck squamous cell carcinoma (HNSCC) is an aggressive and
recurrent malignancy. Identification of unique or overexpressed cell-associated or cell surface
antigens is critical for diagnosis and development of cancer vaccines and targeted therapies for
HNSCC. We have used high throughput microarray technology to search for candidate targets in
HNSCC.
Methods: Gene expression profiling in 17 HNSCC tumors and 3 normal tonsil tissues was
performed by microarray. QRT-PCR analysis was performed to validate the microarray results.
The five candidate genes were further characterized by immunohistochemical technique in surgical
samples and tissue arrays.
Results: A total of 192 up-regulated genes at statistical significance of p < 0.01 and log2 ratio ≥ 1
were identified in HNSCC tumors compared to normal tissues. These genes belong to immune
response, cell growth, cell cycle regulation, oncogenes, metabolism and others. Five potential novel
target genes (FABP5, CD24, CD44, CD74, and HSP27) were identified, which were highly
expressed in HNSCC tumor samples and tissue arrays. CD24, CD44, and CD74 proteins were
expressed on the cell surface, and FABP5 and HSP27 proteins were predominantly expressed in
the cytoplasm of HNSCC.
Conclusion: Five genes and their products may serve as a diagnostic biomarker or therapeutic
target for HNSCC. While additional work is needed to elucidate the biological significance of these
proteins, CD24 and CD74 expressed only in small proportion of cells indicating tumor
heterogeneity and subtypes of tumor initiating cells (CD24+/CD44+) present in HNSCC.
Background
In the United States, an estimated 40,000 new cases of
head and neck cancers are diagnosed each year [1]. More
than 90% of head and neck cancers are of squamous cell
carcinoma, and arise from diverse anatomical locations,
including lip/oral cavity, nasopharynx, oropharynx, lar-
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ynx, and hypopharynx [1,2]. Although numerous studies
have reported on the mechanism of oncogenesis, the pre-
cise cellular mechanism of tumor development, tumor
progression, and tumor aggressiveness are not known.
The survival rate of patients with head & neck squamous
cell carcinoma (HNSCC) has not improved significantly
despite multimodality therapy including surgery, radia-
tion therapy, and chemotherapy. Recent investigations
have focused on novel therapeutic approaches, and on the
identification of molecular targets for therapy [3,4].
Microarray approaches have been widely used to identify
genes associated with tumorigenesis, metastatic potential,
clinically distinct subgroups of tumors, and prognostic
biomarkers and potential targets for novel therapeutic
agents. Identification of unique or overexpressed antigens
or cell surface proteins is critical for the development of
cancer vaccines and targeted immunotoxins or cytotoxins,
which may offer alternative approach for caner therapy.
Previously, our group has identified Interleukin-13 recep-
tor α2 (IL13Rα2) as a unique marker in human head and
neck cancer, which can be used to distinguish a subset of
HNSCC and may serve as a target for immunotoxin or
cytotoxin therapies [5]. In attempt to identify novel thera-
peutic targets for treatments of HNSCC, in the present
study, we analyzed differentially expressed genes in
HNSCC tumors derived from clinical samples, and com-
pared with normal tissues using microarray technology.
The genes significantly up-regulated in HNSCC were
selected as candidates for further evaluation. Based on the
literature and availability of antibody, highly expressed
genes (CD24, CD44, and CD74) encoding cell surface
receptors and (FABP5 and heat shock protein Hsp27)
encoding cytoplasmic proteins were evaluated at protein
levels by IHC. The in-depth analysis of gene expression
and protein expression in tissue arrays of these candidate
genes revealed that they may serve as potential prognostic
biomarkers or therapeutic targets for targeted therapy or
antigen directed immunotherapy.
Methods
Tissue Sample Collection
A total of 17 HNSCC and 3 normal tissues (from tonsil-
lectomies) from 20 patients were collected at Mayo Clinic
Cancer Center. The Institutional Review Board (IRB) of
the Mayo Clinic approved sample collection and RIHSC
(Research Involving Human Subjects Committee) of the
FDA had approved sample receipt at the FDA laboratory.
Samples were immediately stabilized by freezing in liquid
nitrogen in the operating room. All samples were patho-
logically confirmed. The clinical characteristics of the tis-
sue samples are summarized in Table 1. At the FDA
laboratory, the specimen was cut into two pieces, one
piece for RNA isolation and another for paraffin embed-
ding. H & E staining of Paraffin-embedded tissue sections
were performed by Histoserv, Inc (Germantown, MD).
Table 1: Patient demographics and pathology of tumors
Patient # Sex Age (yrs) Tumor Location and Grade History of ETOH or Smoking Pathological Subtypes
Normal Tissues
A9 F 32 tonsillectomy No Follicular hyperplasia
B9 F 30 tonsillectomy ETOH/Smoking Follicular hyperplasia
C9 M 40 tonsillectomy No Follicular hyperplasia
Tumors
A1 / / Base of tongue Grade 3 / Primary SCCA
A6 / / Base of tongue Grade 3 / Primary SCCA
E1 F 68 Base of tongue Grade 4 ETOH/Smoking Recurrent SCCA
I1 M 38 Base of tongue ETOH/Smoking Primary SCCA
F1 F 65 Larynx, Grade 2 ETOH/Smoking Primary SCCA
C1 M 53 Larynx, Grade 3 ETOH/Smoking Primary SCCA
D1 F 40 Larynx, Grade 3 No Metastatic, unknown primary
A3 / / Lymph node-neck / Primary SCCA
A5 / / Lymph node-neck / Primary SCCA
H1 F 44 Lymph node-neck, Grade 3 No Primary SCCA
B1 M 72 Tonsil, Grade 3 No ETOH, Smoking Primary SCCA
B2 M 60 Tonsil ETOH/Smoking Primary SCCA
B5 M 62 Tonsil ETOH/Smoking Primary SCCA
B4 M 53 Buccal mucosa ETOH, Minimal Smoking Recurrent SCCA
G1 M 72 Buccal mucosa Minimal ETOH/Smoking Primary SCCA
A2 M 60 Supraglottic / Primary SCCA
B3 F 72 Supraglottic Grade 4 ETOH/Smoking Recurrent SCCA
/: patient information not available
SCCA: Squamous cell carcinomaHead & Neck Oncology 2009, 1:27 http://www.headandneckoncology.org/content/1/1/27
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Microarray Experiments
Total RNA from tissue samples used for microarray exper-
iments were extracted by Trizol reagent according to the
Manufacture's instructions (Invitrogen). Briefly, tissues
were suspended in Trizol reagent (Invitrogen), homoge-
nized, and RNA was isolated following the Manufacture's
instructions. Human universal RNA (huRNA) (Strate-
gene) was used as a common reference for all experi-
ments. The human microarrays containing approximately
17,000 oligonucleotides were used which were produced
in our laboratory. The detailed information regarding
array printing, post-print processing, and testing array
quality is described elsewhere [6]. Target preparation,
microarray hybridization, image quantification, and data
analyses have been described previously, with modifica-
tions [7]. In brief, 5 μg of total RNA was reverse-tran-
scribed using 5'-amino-modified primers with amino-
allyl-dUTP. cDNAs synthesized from HNSCC tissues sam-
ples were labeled with Cy5 dye, and cDNA from universal
RNA labeled with Cy3 dye. Labeled and combined cDNA
probes were denatured, mixed in SlideHyb #1 hybridiza-
tion buffer (Ambion, Austin, TX), and placed onto micro-
array slides. Arrays were hybridized at 42°C in MAUI
hybridization system (BioMicro Systems) for 16–18
hours, and then washed with 1 × SSC with 0.05% SDS for
4 min., 0.1 × SSC for 4 min. Slides were quickly spin-
dried.
Data Analysis and Statistics
Microarray slides were scanned on a GenePix 4000B scan-
ner (Axon Instruments, Inc., Foster City, CA) with a 10 μm
resolution. Scanned raw images were analyzed and data
files were generated with GenePix Pro 5.1 (Axon) soft-
ware. For analysis, data files were uploaded into mAdb
(microarray database), and analyzed by the software tools
provided by the Center for Information Technology (CIT),
NIH. The advanced filters, spots size at least 30 μm, min-
imum fluorescent intensity of 100 in both Cy3 and Cy5
channels, were applied before data analysis. A standard
global normalization approach was used for each experi-
ment. All of the extracted data was normalized using a
50th percentile (median) normalization method. Statisti-
cal analyses were performed and group comparison t-test
was used to compare the difference of gene expression
between normal and tumor samples. Genes were selected
with the following criteria: p < 0.01, and log2 fold differ-
ence ≥ 1 in mean expression between HNSCC tumors and
normal tissues.
Gene-Specific Confirmation by QRT-PCR
QRT-PCR was performed on selected genes identified by
gene expression profiling. The first-strand cDNA was syn-
thesized from 1 μg of total RNA using Superscript II
Reverse Transcriptase (Invitrogen, Carlsbad, CA) accord-
ing to manufactures specifications. The resulting cDNA
was amplified by using gene-specific primers. Primer
sequences are as follows: FABP5, forward, 5'-agcagct-
ggaaggaagat-3', and reverse, 5'-gatacaatctggcttggc-3';
CD24, forward, 5'-aggatgggattgtggaat-3', and reverse, 5'-
attagtgccgtcgaaaca-3'; EIF4G2, forward, 5'-gcagaagatgcac-
caaac-3', and reverse, 5'-atggctctctgttcctcc-3'; KRT18, for-
ward, 5'-gtagatgcccccaaatct-3', and reverse, 5'-
cactgtggtgctctcctc-3';  LGALS1, forward, 5'-tggactcaatcat-
ggctt-3', and reverse, 5'-ggttgttgctgtctttgc-3'; RPLP0, for-
ward, 5'-gacggattacaccttccc-3', and reverse, 5'-
tggcttcaaccttagctg-3';  GAPDH, forward 5'-aaggtgaaggtcg-
gagtcaa-3', and reverse 5'-gatctcgctcctggaagatg-3'. The spe-
cificity of primers was first verified by RT-PCR and gel
electrophoresis. QRT-PCR reactions were performed with
SYBR Q-PCR master mixture (Stratagene, La Jolla, CA) fol-
lowing the manufactures protocol, and reactions were car-
ried out in a Stratagene Mx3000P machine. Buffer and no
template controls were included in each assay run. All
samples and controls were run in triplicate.
Immunohistochemistry of HNSCC
Immunohistochemical studies of selected genes were per-
formed on both formalin-fixed, paraffin-embedded tissue
sections from patients and HNSCC tissues arrays, which
were purchased from Biomax Inc. Tissue diagnosis of via-
ble tissue was confirmed by H and E staining for squa-
mous cell carcinoma of head and neck. HNSCC tissue
arrays contained 16 cases of primary HNSCC and 8 cases
of cancer adjacent normal tissues in duplicate and
mounted on the slides. Tissue sections or tissue arrays
were deparaffinized by xylene, and then, re-hydrated with
sequential washes of 100%, 75%, and 50% ethanol, and
PBS. For antigen retrieval, slides were placed in 50 mM cit-
rate buffer pH6.0 (Vector Lab, CA), heated in a microwave
oven for 5 min, and then stayed in the buffer for 15 min.
Endogenous peroxidase activity was inhibited with 3%
hydrogen peroxidase in PBS. Non-specific binding was
blocked with 2.5% normal serum and 1% bovine serum
albumin (BSA) for 1 hr. Tissue sections and tissue arrays
were then incubated with various antibodies, CD24,
CD44, and HSP27 (Chemicon; Temecular, CA), CD74
(Santa Cruz Biotech; Santa Cruz, CA), FABP5 (Protein-
Tech; Chicago, IL), or isotype control (IgG) (Sigma) over-
night at 4°C. Immunodetection was performed using
ABC staining systems according to manufacturer's instruc-
tions (Santa Cruz Biotech; Santa Cruz, CA). All sections
were counterstained with haematoxylin. After dehydra-
tion with washes of 95% and 100% ethanol and xylene,
tissue sections and tissue arrays with permanent mount-
ing medium were covered with glass coverslips, and
viewed by light microscope.
Results
Identification of Differentially Expressed Genes in HNSCC
The study population was representative of the general
population with HNSCC, having a median age of 60 years
at presentation. All 17 tumor tissues were squamous cellHead & Neck Oncology 2009, 1:27 http://www.headandneckoncology.org/content/1/1/27
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carcinoma from different locations, and all three tonsil
samples showed follicular hyperplasia (Table 1). Gene
expression profiling was performed in all tumor and nor-
mal tissues. In order to identify the potential therapeutic
targets in HNSCC, we mainly focused on the up-regulated
genes in HNSCC. A total of 192 genes, which were signif-
icantly up-regulated (with p < 0.01 and log2 fold at least ≥
1) in HNSCC tumors compared with normal tonsil tis-
sues, were identified. A number of up-regulated genes
were classified, which belong to various biological proc-
esses including cell growth and proliferation, protein
translation and synthesis, metabolism, signaling, and
immune response (Table 2, and see Additional file 1).
A prominent gene expression signature up-regulated in
HNSCC includes genes associated with inflammation and
immune response, such as MIF, CD74 and CD24, which
were not previously identified in HNSCC (Table 2).
Another prominent signature of up-regulated genes
includes FABP5, HSP27, S100A2, EIF4G2, and RPLP0,
which are associated with various biological functions
such as metabolism, ion binding, and protein translation
and synthesis (Table 2).
To confirm over expressed genes identified by microarray
in HNSCC, six genes including CD24, FABP5, EIF4G2,
LGALS1, KRT18, and RPLP0, were selected and QRT-PCR
analysis was performed. The log-transformed measure-
ment of gene expression levels determined by microarray
positively correlated with the QRT-PCR analysis (Fig 1).
Both microarray and QRT-PCR results confirmed similar
trend of gene expression profile of selected genes in the
HNSCC.
Expression of Selected Gene Products in HNSCC
To narrow down the range of potential therapeutic targets
in 192 up-regulated genes identified in our HNSCC sam-
ples, we mainly focused on the genes encoding cell surface
receptors and some cytoplasmic proteins. Among these
genes, we selected five gene products (CD24, CD44,
CD74, FABP5, and HSP27) as antibodies to these prod-
ucts were available for paraffin embedded tissue sections.
The expression of selected gene products was confirmed
by IHC in tissue sections and tissue arrays. Since CD24,
CD44, and CD74 are cell surface proteins and function as
adhesion molecules, their expression was predominantly
on the cell surface. Nine out of 16 HNSCC tumors in tis-
sue arrays were positive for CD24 expression. However, its
expression was found only in small clusters of cells within
tumors (Fig 2A and 2B). CD44 was strongly expressed on
the cell surface of all tumor cells in all cases of HNSCC
samples (Fig 2D and 2E). CD74 positive cells were also
identified in HNSCC tissue arrays (Fig 2G and 2H). In
contrast, CD24, CD44, or CD74 positive cells were not
detected in adjacent normal tissues present in tissue arrays
(Fig 2C, F, and 2I).
As FABP5 and HSP27 are intra cytoplasmic proteins, their
expression was examined in the cytoplasmic compart-
ment. Both proteins showed strong positive cytoplasmic
staining in majority of cases in the HNSCC tissue arrays
(Fig 2J and 2K, M and 2N). In contrast, only background
staining was observed for either FABP5 or HSP27 in the
adjacent normal tissues (Fig 2L and 2O), except the basal
layer of dermis in normal tissue also showed FABP5 posi-
tive staining (Fig 2L). Isotype control antibody showed no
staining in any section (Data not shown).
Discussion
Global gene expression profiling studies of human
HNSCC tumors have identified genes associated with
tumorigenesis and metastatic potential [8-13]. In addi-
tion, molecular classification of HNSCC has also been
proposed based on gene expression patterns [11-13]. It
has been reported that gene expression profile can distin-
guish clinically distinct subgroups of HNSCC, identify
genes potentially associated with advanced-stage of the
disease, and predict outcome of treatment [9,11,14]. In
our study, in order to identify novel therapeutic targets for
diagnosis or treatments, we compared gene expression in
HNSCC with normal tissues and further characterized
protein expression of over expressed genes in HNSCC
samples. We identified 192 up-regulated genes in HNSCC
compared with normal tissues. Based on our results, pub-
lished literature, and availability of antibody, five candi-
date genes (CD24, CD44, CD74, FABP5, and HSP27)
were selected for further characterization in HNSCC sam-
ples. These gene products were expressed in most tumor
samples but not in normal tissues. Although various stud-
ies have reported on the expression of these genes in vari-
ous tissues, our study presents their significance in
HNSCC tumors.
Among selected genes, CD24, CD44, and CD74 are cell
surface adhesion molecules shown to be over expressed in
various cancers [15-21]. Among these, CD44 was most
strongly expressed in all HNSCC samples in tissue arrays.
Interestingly, CD44+ subpopulation of cells with cancer
stem cell properties has been identified in HNSCC and
various other cancer types [21-25]. CD24 has also been
shown to be expressed in various tumors. Its expression
has been used as a prognostic indicator of poor survival in
breast cancer, non-small cell lung carcinoma, and prostate
cancers [15-18]. However, in contrast to CD44, only a
small portion of CD24+ cells were positive in HNSCC
cancer cells in our study. These results suggest that a subset
of CD24+/CD44+ cells exists, which may represent cancer
stem cells in HNSCC. This hypothesis is supported by a
report which showed that a highly tumorigenic subpopu-
lation of pancreatic cancer cells express cell surface mark-
ers CD44, CD24, and epithelial-specific antigen (ESA)
[23]. This subpopulation of pancreatic cancer cells with
CD44+/CD24+/ESA+ phenotype (only 0.2 to 0.8% ofHead & Neck Oncology 2009, 1:27 http://www.headandneckoncology.org/content/1/1/27
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Table 2: Selected up-regulated genes identified in HNSCC*
GeneBank Access ID Gene Symbol & Annotation Log2 Fold Difference**
Immune Response
L19686 MIF, macrophage migration inhibitory factor 3.1
M13560 CD74, CD74 antigen 2.6
M63438 IGKC, immunoglobulin kappa constant 1.9
J03909 IFI30, interferon, gamma-inducible protein 30 1.5
AJ251549 IL26, interleukin 26 1.4
L33930 CD24, CD24 antigen 1.4
X16302 IGFBP2, insulin-like growth factor binding protein 2 1.4
S75725 IGFBP7, insulin-like growth factor binding protein 7 1.4
Cell Growth, Maintenance/Cell cycle Regulation
Y00503 KRT19, keratin 19 3.9
U43901 LAMR1, laminin receptor 1 3.2
AL031670 FTL, ferritin, light polypeptide 2.5
J00124 KRT14, keratin 14 2.5
X07696 KRT 15, keratin 15 2.4
X95404 CFL1, cofilin 1 2.3
D13627 CCT8, chaperonin subunit 8 2.1
AF026291 CCT4, chaperonin subunit 4 2.0
Z68228 JUP, junction plakoglobin 1.9
M26326 KRT18, keratin 18 1.8
L42583 KRT6C, keratin 6C 1.7
Translation and Protein Synthesis
AK001313 RPLP0, ribosomal protein LP0 4.1
L06499 RPL37A, ribosomal protein L37A 3.9
U73824 EIF4G2, translation initiation factor 4 gamma 2 3.2
M64241 RPL10, ribosomal protein L10 3.2
X69150 RPS18, ribosomal protein S18 3.1
M84711 RPS 3A, ribosomal protein S3A 3.0
NM_000996 RPL35A, ribosomal protein L35A 3.0
U25789 RPL21, ribosomal protein L21 2.9
L11566 RPL18, ribosomal protein L18 2.8
Z21507 EEF1D, eukaryotic translation elongation factor 1D 2.3
AL117412 EIF4A2, eukaryotic translation initiation factor 4A 2.2
AC002544 EIF3S8, eukaryotic translation initiation factor 3, subunit 8 2.1
Metabolism
Z23090 HSPB1, heat shock 27 kDa protein 4.2
M94856 FABP5, fat acid binding protein 5 3.7
NM_021130 PPIA, peptidylprolyl isomerase A (cyclophilin A) 2.9
M26252 PKM2, pyruvate kinase, muscle 2.6
NM_001679 ATP1B3, ATP synthase Na+/K+ transporting, beta 3 2.6
AF061735 ATP5H, ATP synthase H+ transporting subunit 2.1
Y00483 GPX1, glutathione peroxidase 1 2.0
AL021546 COX6A1, cytochrome c oxidase subunit VI a1 1.9
X13923 COX6B, cytochrome c oxidase subunit VI b 1.8
X13794 LDHB, lactate dehydrogenase B 1.7
Z85996 CDKN1A, cyclin-dependent kinase inhibitor 1A 1.7
M60483 PPP2CA, protein phosphatase 2 catalytic subunit 1.7
Y13936 PPM1G, protein phosphatase 1G 1.6
U09813 ATP5G3, ATP synthase H+ transporting subunit 1.6
D29011 PSMB5, proteasome subunit, beta 5 1.6
AF047181 NDUFB5, NADH dehydrogenase beta subcomplex 5 1.5
Ion Binding Proteins
Y07755 S100A2, S100 calcium binding protein A2 3.6
D38583 S100A11, S100 calcium binding protein A11 2.4
NM_020672 S100A14, S100 calcium binding protein A14 1.9Head & Neck Oncology 2009, 1:27 http://www.headandneckoncology.org/content/1/1/27
Page 6 of 9
(page number not for citation purposes)
pancreatic cancer cells) had a 100-fold increased tumori-
genic potential compared with other cancer cells [23].
Future studies will focus on the isolation and characteriza-
tion of the CD24+/CD44+ and other marker positive
tumor subpopulations from HNSCC.
CD74 is another cell surface membrane protein identified
in this study, which was not previously reported in
HNSCC. However, the over expression of CD74 has been
reported in many different malignancies, including gastric
tumors, renal epithelial neoplasms, pancreatic cancers,
certain types of sarcoma and skin cancer, and non-small
cell lung cancers [26-30]. CD74 has been identified as the
high-affinity receptor for the macrophage migration
inhibitory factor [31]. The over expression of macrophage
migration inhibitory factor has also been reported in var-
ious cancers, including lung cancer, breast cancers, pros-
tate cancers, ovarian cancers, colorectal cancers, and
HNSCC tumors in this study (Table 2) [30,32-35]. Over-
expression of tumor cell-derived macrophage migration
inhibitory factor (MIF) in solid tumors is related to tumor
growth, progression, and angiogenesis [32-34,36]. Recent
study on non-small cell lung cancers suggested that the co-
expression of MIF and its receptor CD74 is associated with
greater tumor vascularity and greater of angiogenic CXC
chemokines [30]. In vitro inhibition of MIF or its receptor
resulted in reduced production of angiogenic CXC chem-
okines by lung cancer cells [30]. In addition, the clinical
study in colorectal cancer patients found that the serum
level of MIF was significantly increased in cancer patients,
suggesting that MIF could be used as a diagnostic marker
in colorectal cancers [35]. In our study, since both MIF
and its receptor CD74 are highly expressed in HNSCC,
these results suggest that both MIF and CD74 may poten-
tially serve as valuable biomarkers in HNSCC. In addi-
tion, as a cell membrane protein, CD74 may serve as a
new target for anti-cancer therapy of HNSCC. MIF, on the
other hand, may serve as a new diagnostic marker for
HNSCC.
FABP5 is a fatty acid-binding protein and is expressed in
epidermis and endothelial cells of the microvasculature of
different organs [37]. FABP5 has also been identified as a
tumor-associated antigen, which is highly expressed in
various cancers [38,39]. FABP5 was detected in the sera of
HNSCC patients with early stage cancer [40]. Antibodies
specific for FABP5 were significantly increased in a sub-
stantial amount in patients, suggesting that FABP5 may be
a potential diagnostic biomarker for HNSCC [40]. As
FABP5 is highly expressed at both mRNA and protein lev-
X99920 S100A13, S100 calcium binding protein A13 1.2
Others
M14328 ENO1, enolase 1 3.3
M26880 UBC, ubiquitin C 3.2
S54005 TMSB10, thymosin, beta 10 2.8
D87953 NDRG1, M-myc downstream regulated gene 1 2.4
M36981 NME2, non-metastatic cells 2 protein 2.3
AF055008 GRN, granulin 2.3
X57348 SFN, stratifin 2.3
U46751 SQSTM1, sequestosome 1 2.2
X67951 PRDX1, peroxiredoxin 1 2.1
X65607 MT1X, metallothionein 1X 1.5
X84709 FADD, Fas associated death domain 1.2
* All selected genes with p-value < 0.01.
**Log2 ratio fold-differences between tumors and normal tissues were determined by subtracting the ratio of genes in normal tissue versus uRNA 
from the ratio of genes in HNSCC tissues versus uRNA. (Log2 ratio of 1 equals to 2-fold difference between HNSCC and normal tissue; Log2 ratio 
of 2 equals to 4-fold difference between HNSCC and normal tissue, and so on)
Table 2: Selected up-regulated genes identified in HNSCC* (Continued)
Real-Time PCR confirmation of selected genes Figure 1
Real-Time PCR confirmation of selected genes. The 
open bar represents expression ratio compared to huRNA 
control from microarray experiments, and solid bar presents 
the ratio from QRT-PCR experiments. Results indicate simi-
lar trend of gene expression in both microarray and QRT-
PCR experiments.
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Microarray
Q-PCR
Log2 Ratio
CD24
EIF4G2
FABP5
KRT18
LGALS1
RPLP0Head & Neck Oncology 2009, 1:27 http://www.headandneckoncology.org/content/1/1/27
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els in HNSCC compared to normal tissues, our results
support previous suggestion that FABP5 may serve as a
biomarker for HNSCC.
Another interesting gene identified in HNSCC is heat
shock protein (HSP27). Over expression of HSP27 in
HNSCC was not reported previously, although HSPs have
been reported to be over-expressed in a wide range of
human cancers, which suggest that HSPs may serve as an
effective target for therapy [41,42]. In addition, over
expression of HSP has been correlated with a poor prog-
nosis in terms of survival and response to therapy in spe-
cific cancer types [41,43,44]. HSP27 is associated with
poor prognosis in gastric cancer, liver cancer, prostate car-
cinoma, and non-small cell lung carcinoma [41,44].
HSP27 is also implicated in resistance to chemotherapy in
breast cancer [41]. Several small-molecule drugs that tar-
get the HSP27 have been identified as potential anticancer
agents [45]. Thus, up-regulation of HSP27 in HNSCC
tumors identified in our current study provides opportu-
nities for a new biomarker of disease monitoring and
development of new targeted therapy for HNSCC.
Conclusion
In this study, global gene expression profiling approach
has been used to identify a large number of differentially
expressed genes in HNSCC tumors compared to normal
tissues. Among differentially expressed genes, we charac-
terized five potential valuable targets for therapy and
monitoring. These genes are expressed in the primary
tumors. Future studies will be focused on the expression
of these target genes in primary and metastatic lesions of
HNSCC, and the impact of conventional therapies, such
as chemotherapy or radiotherapy on the expression of
these genes. While additional work is ongoing to elucidate
the biological significance, our results suggest that CD24,
CD44, CD74, and HSP27 may serve as new valuable ther-
apeutic targets for the treatment of HNSCC; and FABP5
and MIF may be potential diagnostic markers for HNSCC.
Our results also demonstrate that there may be a poten-
tially new subpopulation (CD24+/CD44+) of tumor initi-
ating cells in HNSCC.
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Gene expression changes in HNSCC compared to normal tonsils. Data 
show up-regulated genes, with p-value < 0.01 and log2 ratio ≥ 1, in 
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Click here for file
[http://www.biomedcentral.com/content/supplementary/1758-
3284-1-27-S1.doc]
Immunohistochemical analysis of CD24, CD44, CD74,  FABP5, and Hsp27 in HNSCC samples Figure 2
Immunohistochemical analysis of CD24, CD44, 
CD74, FABP5, and Hsp27 in HNSCC samples. 
HNSCC tissue arrays contained 16 tumor samples from vari-
ous locations and different stages. A and B are tumor sam-
ples and stained for CD24. D and E stained for CD44, and 
showed strong positive reactions in most tumor cells. Both 
CD24+ and CD44+ show cell surface staining, and CD24+ 
cells present in a small cluster of cells in the large tumor 
mass. (Magnification: ×200). G and H stained for CD74. 
Some of tumor cells showed CD74+. J and K stained for 
FABP5, and M and N stained for Hsp27. FABP5 shows strong 
cytoplasmic staining as well as Hsp27. C, F, I, L, O: tumor 
adjacent normal tissue. CD24, CD44, CD74, FABP5, and 
Hsp27 were negative in normal tissues, although FABP5 
shows positive staining in the basal layer of dermis (Fig 2L), 
but negative in other areas; (Magnification: ×200). IgG was 
used as a negative control (Data not shown).
CD24
CD44
CD74
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